Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Operating Expenses: 2020-2025

Historic Operating Expenses for Tango Therapeutics (TNGX) over the last 6 years, with Sep 2025 value amounting to $39.7 million.

  • Tango Therapeutics' Operating Expenses fell 10.67% to $39.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $176.8 million, marking a year-over-year decrease of 3.41%. This contributed to the annual value of $187.7 million for FY2024, which is 24.53% up from last year.
  • Latest data reveals that Tango Therapeutics reported Operating Expenses of $39.7 million as of Q3 2025, which was down 9.99% from $44.1 million recorded in Q2 2025.
  • Tango Therapeutics' Operating Expenses' 5-year high stood at $49.4 million during Q2 2024, with a 5-year trough of $18.5 million in Q1 2021.
  • Moreover, its 3-year median value for Operating Expenses was $44.1 million (2025), whereas its average is $42.7 million.
  • Per our database at Business Quant, Tango Therapeutics' Operating Expenses spiked by 4,811,128.81% in 2021 and then dropped by 10.68% in 2025.
  • Tango Therapeutics' Operating Expenses (Quarterly) stood at $27.7 million in 2021, then skyrocketed by 33.49% to $37.0 million in 2022, then grew by 9.37% to $40.4 million in 2023, then climbed by 11.33% to $45.0 million in 2024, then dropped by 10.67% to $39.7 million in 2025.
  • Its Operating Expenses stands at $39.7 million for Q3 2025, versus $44.1 million for Q2 2025 and $47.9 million for Q1 2025.